Leela Biotechandindustries Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 01-01-2025
- Paid Up Capital ₹ 0.51 M
as on 01-01-2025
- Company Age 29 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2017)
- Profit -225.80%
(FY 2017)
- Ebitda -3282.58%
(FY 2017)
- Net Worth -0.15%
(FY 2017)
- Total Assets -13.29%
(FY 2017)
About Leela Biotechandindustries
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 0.51 M, as per Ministry of Corporate Affairs (MCA) records.
Chandrasekaran Swaminathan, Hemamalini, and Rajesh Sahani serve as directors at the Company.
- CIN/LLPIN
U51909KA1995PLC017742
- Company No.
017742
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
03 May 1995
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Leela Biotechandindustries?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chandrasekaran Swaminathan  | Director | 01-Dec-2009 | Current |
| Hemamalini | Director | 19-May-2010 | Current |
| Rajesh Sahani | Director | 18-Sep-2015 | Current |
Financial Performance of Leela Biotechandindustries.
Leela Biotechandindustries Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 225.8% decrease in profit. The company's net worth dipped by a decrease of 0.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Leela Biotechandindustries?
In 2017, Leela Biotechandindustries had a promoter holding of 0.79% and a public holding of 99.21%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Hester Agrhotech Internaational LimitedActive 30 years 15 daysChandrasekaran Swaminathan is a mutual person
- Madhu Infra Developers Private LimitedActive 16 years 9 months
Chandrasekaran Swaminathan is a mutual person
- Carus Trading Private LimitedActive 34 years 11 months
Chandrasekaran Swaminathan is a mutual person
- Gummalapuram Estates Private LimitedActive 17 years 7 months
Chandrasekaran Swaminathan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Leela Biotechandindustries?
Unlock and access historical data on people associated with Leela Biotechandindustries, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Leela Biotechandindustries, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Leela Biotechandindustries's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
